204 related articles for article (PubMed ID: 12297947)
1. [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Frick S; Lischner S; Rosien F; Haacke TC; Schäfer F; Christophers E; Hauschild A
Hautarzt; 2002 Oct; 53(10):659-65. PubMed ID: 12297947
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Hofmann M; Kiecker F; Wurm R; Schlenger L; Budach V; Sterry W; Trefzer U
J Neurooncol; 2006 Jan; 76(1):59-64. PubMed ID: 16132502
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Lewis KD; Gibbs P; O'Day S; Richards J; Weber J; Anderson C; Zeng C; Baron A; Russ P; Gonzalez R
Cancer Invest; 2005; 23(4):303-8. PubMed ID: 16100942
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Margolin K; Atkins B; Thompson A; Ernstoff S; Weber J; Flaherty L; Clark I; Weiss G; Sosman J; II Smith W; Dutcher P; Gollob J; Longmate J; Johnson D
J Cancer Res Clin Oncol; 2002 Apr; 128(4):214-8. PubMed ID: 11935312
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Guillot B; Khamari A; Cupissol D; Delaunay M; Bedane C; Dreno B; Picot MC; Dereure O
Melanoma Res; 2008 Apr; 18(2):141-6. PubMed ID: 18337651
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
[TBL] [Abstract][Full Text] [Related]
8. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Schadendorf D; Hauschild A; Ugurel S; Thoelke A; Egberts F; Kreissig M; Linse R; Trefzer U; Vogt T; Tilgen W; Mohr P; Garbe C
Ann Oncol; 2006 Oct; 17(10):1592-7. PubMed ID: 17005632
[TBL] [Abstract][Full Text] [Related]
9. Metastatic melanoma: a regional review and future directions.
Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?
Boogerd W; de Gast GC; Dalesio O
Cancer; 2007 Jan; 109(2):306-12. PubMed ID: 17149755
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of malignant melanoma at the stage of distant metastasis].
Garbe C; Eigentler TK
Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
[TBL] [Abstract][Full Text] [Related]
12. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
13. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Bafaloukos D; Tsoutsos D; Fountzilas G; Linardou H; Christodoulou C; Kalofonos HP; Briassoulis E; Panagiotou P; Hatzichristou H; Gogas H
Melanoma Res; 2004 Aug; 14(4):289-94. PubMed ID: 15305160
[TBL] [Abstract][Full Text] [Related]
14. Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Dvorak J; Melichar B; Zizka J; Hadzi-Nikolov D; Petera J
Onkologie; 2004 Apr; 27(2):171-4. PubMed ID: 15138351
[TBL] [Abstract][Full Text] [Related]
15. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Melanoma Res; 2006 Aug; 16(4):357-63. PubMed ID: 16845332
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
[TBL] [Abstract][Full Text] [Related]
18. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Teimouri F; Nikfar S; Abdollahi M
Melanoma Res; 2013 Oct; 23(5):381-9. PubMed ID: 23880781
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]